98%
921
2 minutes
20
Relapse is one of the major challenges in clinical treatment of acute myeloid leukemia (AML). Though minimal residual disease (MRD) monitoring plays a crucial role in quantitative assessment of the disease, molecular MRD analysis has been mainly limited to patients diagnosed with gene fusions and NPM1 mutations. Here, we report a longitudinal ultra-sensitive mutation burden (UMB) monitoring strategy for accurate MRD analysis in AML patients regardless of genetic abnormality types. Using a Quantitative Blocker Displacement Amplification (QBDA) sequencing panel with limit of detection below 0.01% variant allele frequency (VAF), a hazard ratio of 14.8 (p < 0.001) is observed in cumulative incidence of relapse analysis of 20 patients with ≥ 2 samples during complete remission (CR). The ROC area under curve (AUC) is 0.98 when predicting relapse within 30 weeks of CR timepoint 2 (N = 20). Furthermore, we demonstrate quantitating VAF below 0.01% is essential for accurate relapse prediction.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11564880 | PMC |
http://dx.doi.org/10.1038/s41467-024-54254-6 | DOI Listing |
A graded hollow-core optical microcavity (GHCOM) functionalized by polyA-AuNPs is proposed and demonstrated for DNA hybridization detection with ultra-low limit of detection (LoD) and high specificity. The GHCOM with wall thickness of ∼2 μm and Q factor of 7.8 × 10 is fabricated, featuring a graded longitudinal shape which enhances light-matter interaction near sensing interface of the microcavity.
View Article and Find Full Text PDFMol Neurobiol
September 2025
Department of Neurology, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, Institute of Neuroscience, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510260, China.
The assay of plasma biomarkers plays a role in the assessment of Alzheimer's disease (AD) and the monitoring of treatments. One of the ultra-sensitive assay technologies is the so-called immunomagnetic reduction (IMR). According to published papers, plasma amyloid β peptide (Aβ) and total tau protein (T-Tau) are crucial biomarkers.
View Article and Find Full Text PDFEBioMedicine
January 2025
Malaria Elimination Initiative, Global Health Group, University of California, San Francisco (UCSF), San Francisco 94158, USA; Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas 75390, USA; Department of Pediatrics, UCSF Benioff Children's Hospital, San Francisco 94158
Arch Gynecol Obstet
December 2024
Department of Assisted Reproductive Technologies and Fertility Preservation, Jeanne de Flandre Hospital, CHU Lille, 59000, Lille, France.
Introduction: Ovarian tissue cryopreservation (OTC) is recommended by scientific societies for women undergoing highly gonadotoxic cancer treatments. Following transplantation, the restoration of ovarian function is typically characterised by the resumption of spontaneous menstruation. Yet, a few studies have looked at the longitudinal hormonal variations following transplantation.
View Article and Find Full Text PDFNat Commun
November 2024
School of Pharmaceutical Sciences, Capital Medical University, Beijing, China.
Relapse is one of the major challenges in clinical treatment of acute myeloid leukemia (AML). Though minimal residual disease (MRD) monitoring plays a crucial role in quantitative assessment of the disease, molecular MRD analysis has been mainly limited to patients diagnosed with gene fusions and NPM1 mutations. Here, we report a longitudinal ultra-sensitive mutation burden (UMB) monitoring strategy for accurate MRD analysis in AML patients regardless of genetic abnormality types.
View Article and Find Full Text PDF